Coya Therapeutics (NASDAQ:COYA) Receives “Buy” Rating from Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research note published on Friday,Benzinga reports. They currently have a $14.00 price target on the stock.

Several other equities analysts also recently commented on COYA. D. Boral Capital reiterated a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a report on Friday, April 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Monday, April 20th. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research report on Monday, March 23rd. Roth Mkm started coverage on Coya Therapeutics in a research report on Friday, June 5th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, Wall Street Zen cut Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $15.33.

Coya Therapeutics Trading Up 2.2%

NASDAQ COYA opened at $4.74 on Friday. The stock has a market cap of $111.20 million, a P/E ratio of -4.12 and a beta of 0.62. The company’s fifty day simple moving average is $4.50 and its 200-day simple moving average is $4.85. Coya Therapeutics has a 52 week low of $3.71 and a 52 week high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.07. Coya Therapeutics had a negative net margin of 266.10% and a negative return on equity of 55.86%. The business had revenue of $0.25 million during the quarter, compared to analyst estimates of $0.15 million. On average, research analysts expect that Coya Therapeutics will post -1.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

Hedge funds have recently made changes to their positions in the stock. Prosperity Wealth Management Inc. raised its stake in shares of Coya Therapeutics by 16.4% in the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after buying an additional 3,350 shares during the period. JPMorgan Chase & Co. bought a new stake in shares of Coya Therapeutics in the third quarter valued at $28,000. Cetera Investment Advisers raised its stake in shares of Coya Therapeutics by 36.4% in the first quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock valued at $118,000 after buying an additional 8,000 shares during the period. CIBC Private Wealth Group LLC bought a new stake in shares of Coya Therapeutics in the fourth quarter valued at $47,000. Finally, Occudo Quantitative Strategies LP bought a new stake in shares of Coya Therapeutics in the fourth quarter valued at $66,000. 39.75% of the stock is currently owned by institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.